hr 52811
About Company
Canton Biologics (hereinafter as CANTON) is a biologics CDMSO providing one-stop services from early discovery to commercialization for biopharmaceutical companies worldwide. CANTON has developed pioneering technology platforms. CANTON specializes in the study of difficult-to-express proteins, including recombinant proteins, fusion proteins and bsAbs. CANTON has made significant technological breakthroughs in lgM molecular expression platforms, expression host cells, high-density cell culture, novel formulations, and analytical assays, and has set a new record of completing the pilot production from DNA in only 7 months. In terms of commercial production, CANTON has 12+4 independent production lines that comply with Chinese, American and European GMP standards, with capacity of 50-2500L DS and DP production.
